223 related articles for article (PubMed ID: 36159870)
1. Improvement of gut microbiome and intestinal permeability following splenectomy plus pericardial devascularization in hepatitis B virus-related cirrhotic portal hypertension.
Zhao Y; Zhou R; Guo Y; Chen X; Zhang A; Wang J; Ji F; Qin B; Geng J; Kong G; Li Z
Front Immunol; 2022; 13():941830. PubMed ID: 36159870
[TBL] [Abstract][Full Text] [Related]
2. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma.
Tang Y; Zhou H; Xiang Y; Cui F
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e167-e175. PubMed ID: 33208683
[TBL] [Abstract][Full Text] [Related]
4. Indocyanine green retention is a potential prognostic indicator after splenectomy and pericardial devascularization for cirrhotic patients.
Zhang YB; Lu Y; Wu WD; Zhang CW; Shen GL; Hong dF
Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):386-90. PubMed ID: 27498578
[TBL] [Abstract][Full Text] [Related]
5. Gut-liver axis signaling in portal hypertension.
Simbrunner B; Mandorfer M; Trauner M; Reiberger T
World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Study to Compare Selective Decongestive Devascularization and Gastrosplenic Shunt versus Splenectomy with Pericardial Devascularization for the Treatment of Patients with Esophagogastric Varices Due to Cirrhotic Portal Hypertension.
Bao H; He Q; Dai N; Ye R; Zhang Q
Med Sci Monit; 2017 Jun; 23():2788-2795. PubMed ID: 28594784
[TBL] [Abstract][Full Text] [Related]
7. Improvement of human platelet aggregation post-splenectomy with paraesophagogastric devascularization in chronic hepatitis B patients with cirrhotic hypersplenism.
Zhang H; Zhang S; Zhang J; Zhou R; Nie Y; Ren S; Li J; Feng K; Ji F; Kong G; Li Z
Platelets; 2020 Nov; 31(8):1019-1027. PubMed ID: 31851564
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis.
Shu W; Shanjian C; Jinpiao L; Qishui O
Ann Hepatol; 2022; 27(2):100676. PubMed ID: 35093600
[TBL] [Abstract][Full Text] [Related]
9. Circulating microbiome in patients with portal hypertension.
Gedgaudas R; Bajaj JS; Skieceviciene J; Varkalaite G; Jurkeviciute G; Gelman S; Valantiene I; Zykus R; Pranculis A; Bang C; Franke A; Schramm C; Kupcinskas J
Gut Microbes; 2022; 14(1):2029674. PubMed ID: 35130114
[TBL] [Abstract][Full Text] [Related]
10. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response.
Yan F; Zhang Q; Shi K; Zhang Y; Zhu B; Bi Y; Wang X
Front Cell Infect Microbiol; 2023; 13():1152987. PubMed ID: 37201112
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
[TBL] [Abstract][Full Text] [Related]
13. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
14. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model.
Li X; Wu S; Du Y; Yang L; Li Y; Hong B
Int J Antimicrob Agents; 2020 Jul; 56(1):106000. PubMed ID: 32360229
[TBL] [Abstract][Full Text] [Related]
15. Splenectomy Leads to Amelioration of Altered Gut Microbiota and Metabolome in Liver Cirrhosis Patients.
Liu Y; Li J; Jin Y; Zhao L; Zhao F; Feng J; Li A; Wei Y
Front Microbiol; 2018; 9():963. PubMed ID: 29867867
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Gut Microbiome Contributes to Intestinal Oxidative Stress, Barrier Dysfunction, Inflammation and Systemic Autoimmune Responses in MRL/lpr Mice.
Wang H; Wang G; Banerjee N; Liang Y; Du X; Boor PJ; Hoffman KL; Khan MF
Front Immunol; 2021; 12():651191. PubMed ID: 33912174
[TBL] [Abstract][Full Text] [Related]
17. [Laparoscopic splenectomy and pericardial devascularization for treatment of portal hypertension due to liver cirrhosis].
Hong DF; Zheng XY; Peng SY; Gao M; Wu JG; Cao Q
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(12):820-2. PubMed ID: 17565864
[TBL] [Abstract][Full Text] [Related]
18. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.
Bajaj JS; Betrapally NS; Hylemon PB; Heuman DM; Daita K; White MB; Unser A; Thacker LR; Sanyal AJ; Kang DJ; Sikaroodi M; Gillevet PM
Hepatology; 2015 Oct; 62(4):1260-71. PubMed ID: 25820757
[TBL] [Abstract][Full Text] [Related]
19. Effects of early antiplatelet therapy after splenectomy with gastro-oesophageal devascularization.
Zhou JB; Luo BY; Liu CW; Zhu F
ANZ J Surg; 2018 Oct; 88(10):E725-E729. PubMed ID: 29396900
[TBL] [Abstract][Full Text] [Related]
20. Exploratory Research on the Relationship between Human Gut Microbiota and Portal Hypertension.
Yokoyama K; Tsuchiya N; Yamauchi R; Miyayama T; Uchida Y; Shibata K; Fukuda H; Umeda K; Takata K; Tanaka T; Inomata S; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
Intern Med; 2020; 59(17):2089-2094. PubMed ID: 32879200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
